J Korean Cancer Assoc.  2000 Dec;32(6):1050-1058.

p21WAF1/CIP1 Codon 31 Polymorphism in Korean Women: Association with Cervical Cancer Susceptibility and Prognosis

Affiliations
  • 1Department of Obstetrics and Gynecology, College of Medicine, Seoul National University, Seoul, Korea.

Abstract

PURPOSE: The aim of this study was to determine whether certain genotype of p21WAF1/Cip1 might be associated with risk of cervical cancer in Korean women.
MATERIALS AND METHODS
We used the specimens derived from cervical cancer (n=111) composed of two histologic groups; SCCA (n=67) and adenocarcinoma (n=44), CIN III (n=101) and controls (n=98). For the determination of p21WAF1/Cip1 polymorphism, DNA was examined by PCR-RFLP using BsmAI. We compared the distribution of p21WAF1/Cip1 genotype of Korean women with that of other ethnic groups and analyzed the distribution of invasive cancer, CIN III and controls.
RESULTS
The genotype frequency of controls was different from that of Caucasian and Chinese (p<0.001) but similar to that of Japanese (p=0.21). There was no difference in the genotype frequency of p21WAF1/Cip1 among SCCA, CIN III and controls (p>0.05). A significant increase of Ser/Ser genotype was found in adenocarcinoma patients with high-risk HPV compared with the controls (p=0.009). The OR was 3.59, 95% CI=1.55~8.31, when comparing that group with controls. However, we could not find differences of prognosis.
CONCLUSION
We found that codon 31 Ser/Ser homozygote of the p21WAF1/Cip1 would be a risk factor for the adenocarcinoma of cervix associated with high-risk HPV in Korean women.

Keyword

p21WAF1/Cip1; Polymorphism; Cervical neoplasm

MeSH Terms

Adenocarcinoma
Asian Continental Ancestry Group
Cervix Uteri
Codon*
DNA
Ethnic Groups
Female
Genotype
Homozygote
Humans
Prognosis*
Risk Factors
Uterine Cervical Neoplasms*
Codon
DNA
Full Text Links
  • JKCA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr